REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/01/2025
Back to search
Official data from USPTO
DIRECTMX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
DIRECTMX
ST13
US500000088614061Class
1, 5, 40, 42
Filing
88614061
Registration
6208690
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
12/02/2025
Trademark type
Word
Nice classes
1, 5, 40, 42
Filing date
09/12/2019
Registration date
12/01/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/01/2020
Last transaction
12/02/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
03
Owner location
Stockholm, SE
Examiner
LE, MARGARET
Law office
M90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
SALIPRO BIOTECH AB
Representatives
Timothy P. Naill REINHART BOERNER VAN DEUREN P.C.
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological preparations for use in industry; Biological preparations for use in science; Carriers for biologically active compounds; Biological substancesmaterialspreparations and elements for scientific and industrial use in vivo and in vitro; Chemical substanceschemical materials and chemical preparationsnatural elements for scientific and industrial use in vivo and in vitro; biological materials for use in industry and science; Chemical substancesmaterialspreparations and elements for cosmetic preparations; Biological substancesmaterialspreparations and elements for cosmetic preparations; Lipid nanoparticles for use in industry and science; Lipid nanoparticles comprising protein for use in industry and science; Saposin-lipid nanoparticles for use in industry and science
Class 5
Biochemical preparations for preventing or treating infectious or parasitic diseasescancerdiseases of the blood and blood-forming organsendocrinenutritional and metabolic diseasesmental and behavioral disordersdiseases of the nervous systemdiseases of the eyediseases of the eardiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary system and autoimmune diseases; Biochemical preparations for preventing or treating infectious or parasitic diseasescancerdiseases of the blood and blood-forming organsendocrinenutritional and metabolic diseasesmental and behavioral disordersdiseases of the nervous systemdiseases of the eyediseases of the eardiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary system and autoimmune diseases in non-human animals; Biological reagents for medical use; Biological reagents for veterinary use; Carriers for pharmaceuticalmedicalveterinary or diagnostic compounds; Biochemical preparations for preventing or treating infectious or parasitic diseasescancerdiseases of the blood and blood-forming organsendocrinenutritional and metabolic diseasesmental and behavioral disordersdiseases of the nervous systemdiseases of the eyediseases of the eardiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary system and autoimmune diseases in humans and non-human animals and for use in a diagnostic method; Medicinal preparations and substances for preventing or treating infectious or parasitic diseasescancerdiseases of the blood and blood-forming organsendocrinenutritional and metabolic diseasesmental and behavioral disordersdiseases of the nervous systemdiseases of the eyediseases of the eardiseases of the circulatory systemdiseases of the respiratory systemdiseases of the digestive systemdiseases of the skin and subcutaneous tissuediseases of the musculoskeletal system and connective tissuediseases of the genitourinary system and autoimmune diseases in humans and non-human animals; Veterinary vaccines; Human vaccine preparations; Lipid nanoparticles for medicinaldiagnostic or pharmaceutical purposes; Lipid nanoparticles comprising protein for medicaldiagnostic or pharmaceutical purposes; Saposin-lipid nanoparticles for medicaldiagnostic or pharmaceutical purposes
Class 40
Treatment of cells and/or viruses and/or biological membranes to obtain carriers for biologically activepharmaceutical or diagnostic compounds; Conversion of cells and/or viruses and/or biological membranes into biochemical preparations; Custom manufacturing of lipid nanoparticles in particular of lipid nanoparticles comprising protein or Saposin-lipid nanoparticles; Processing of cells and/or viruses and/or biological membranes for third parties
Class 42
Biological laboratory services; Biochemistry consultancy; Consulting services in the field of lipid nanoparticles in particular in the field of lipid nanoparticles comprising protein or Saposin-lipid nanoparticles
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/01/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/15/2020
PUBO
PUBLISHED FOR OPPOSITION
09/15/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/26/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/09/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
08/09/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/09/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
08/09/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/09/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/24/2020
GNSL
LETTER OF SUSPENSION E-MAILED
06/24/2020
CNSL
SUSPENSION LETTER WRITTEN
06/24/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/15/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/15/2020
ALIE
ASSIGNED TO LIE
06/15/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/04/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/19/2019
GNRT
NON-FINAL ACTION E-MAILED
12/19/2019
CNRT
NON-FINAL ACTION WRITTEN
12/19/2019
DOCK
ASSIGNED TO EXAMINER
12/13/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/20/2019
NWAP
NEW APPLICATION ENTERED
09/16/2019
Continuous trademark protection
Get notified about every new filing that threatens DIRECTMX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.